We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genosis | LSE:GNOS | London | Ordinary Share | GB00B0NVFD79 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.125 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:2191B Genosis PLC 31 July 2007 For Immediate Release 31 July 2007 GENOSIS PLC ANNUAL GENERAL MEETING AND TRADING UPDATE The Annual General Meeting was held today for Genosis PLC (AIM: GNOS) the company specialising in consumer products for reproductive health. After the formal proceedings of the meeting were completed, in which all resolutions were passed, Dr Joe Blaker, the Chairman, provided the following trading update to shareholders. Genosis is pleased to announce that sales in the first six months to June 2007 were #503,000, more than two and a half times sales of the same period last year. This growth in sales is due to two key factors, the launch of the Fertell ovarian reserve test in the UK market and the launch on 4th June 2007 of the Fertell couples test into the US market. As previously announced, the US drug store chains CVS and Longs Drugs are distributing the Fertell couples test throughout the US. Initial stocking orders amounted to 7,250 units and, as at 30th June 2007, the distributors had ordered a further 3,400 units. Web sales in the US for the period to 30th June 2007 were approximately 870 units. The launch of the Fertell test in the US was well received in the press and media with as many as 24 of the 25 National TV networks mentioning the product. Of particular note was Fertell being featured in a prime time slot on ABC's network news programme "Good Morning America". Whilst the ordering levels in June were below expectations, the ongoing PR campaign and the July start of the print media programme should result in growing orders of the product throughout the second half of the year and beyond. Sales in the UK continue in line with expectations through the Company's exclusive agreement with Alliance Boots. Genosis announced recently the successful completion of a secondary funding round raising #2.3 million (gross) which was supported by existing and new investors. This has strengthened the Group's balance sheet and will enable Genosis to increase its marketing activities in the US over the next 12 months. As at 30 June 2007 Genosis had cash in hand of #3.2 million. For further details, please contact: Genosis PLC Paul Bateman, CEO +44 (0)1483774058 Jonathan Pockson, CFO Buchanan Communications Lisa Baderoon +44 (0)2074665000 Rebecca Skye Dietrich Evolution Securities Tim Worlledge +44 (0)2070714300 Bobbie Hilliam This information is provided by RNS The company news service from the London Stock Exchange END MSCSDUFLFSWSEEW
1 Year Genosis Chart |
1 Month Genosis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions